

**Open Public Hearing Speakers for May 11, 2001
Joint Meeting - Nonprescription Drugs Advisory Committee &
Pulmonary - Allergy Drugs Advisory Committee**

Petition 98P-0610/CP1 - submitted by Blue Cross of California requesting
fexofenadine hydrochloride, loratadine and cetirizine hydrochloride be switched to OTC status

All speakers have been asked to limit their comments to five minutes. All speakers have also been asked to disclose their possible sources of conflict of interest before beginning their presentation.

Session 1: 10:15-11am

Allergists

Eric Schenkel, M.D., Director, Valley Allergy and Asthma Treatment Center, Easton, Pennsylvania

Steven Weinstein, M.D., Professor of Pediatrics, Division of Allergy and Immunology, College of Medicine, University of California at Irvine

Diagnostic Testing

Ivor Emanuel, M.D., Clinical Assistant Professor, Department of Otolaryngology, University of California, San Francisco, representing Pharmacia Diagnostics

Pharmacist

Daniel Hussar Ph.D., Remington Professor of Pharmacy, Philadelphia College of Pharmacy

Managed Care

Charles Cutler, M.D., Chief Medical Officer, American Association of Health Plans

Health Consultants to Employers

Frank Brocato, President/CEO, Employers Health Coalition, Tampa Florida

Coalition representing consumer, provider and employer

Mark Cloutier, MPH, MPP, Policy Director, RXHealthValue

.....
Session 2: 1-2pm (after the lunch break)

Professional Associations

Michael Parker, M.D., American Academy of Otolaryngic Allergy (AAOA)

Bobby Lanier, M.D., American Academy of Asthma, Allergy and Immunology (AAAAI) and College of Allergy, Asthma and Immunology

J.A. Quel, M.D., Executive Director, Hispanic American Allergy, Asthma, Immunology Association (HAAMA)

Michael Kaliner, M.D., Vice President of the World Allergy Association

Patient Advocacy

Nancy Sander, Allergy and Asthma Network Mothers of Asthmatics

Richard Carson, Asthma and Allergy Foundation of America

Manufacturer of Current OTC Antihistamines

Phil Walson, M.D., University of Cincinnati, Director of Clinical Trials, Children's Hospital representing Whitehall Robins

Health Consultants

Bryan Luce, Ph.D., MEDTAP International

Joel W. Hay, Ph.D., Department of Pharmaceutical Economics and Policy, USC and Editor-In-Chief of *Value in Health*

Steve Francesco, President Francesco International; newsletter SWITCH

Trade Organizations

Bert Spilker, M.D., Senior Vice President for Science and Regulatory Affairs of the Pharmaceutical Research and Manufacturers of America (PhRMA)

R. William Soller, Ph.D., Senior Vice President and Director of Science and Technology, Consumer Healthcare Products Association (CHPA)